Rheumatology

James Woody, MD, PhD, explains the benefits of treating Dupuytren’s disease with anti-tumor necrosis factor (TNF).

Data from 2 studies evaluating adults with active psoriatic arthritis were announced today in preparation for EULAR 2022. The different population groups who received treatment were biologic-naive patients and TNF-inadequate responders.

Janet E McDonagh, MD, FRCP explains the importance of obtaining both the patient and parent perspective in pediatric rheumatology.

Take 5 minutes to catch up on Rheumatology Network's highlights from the week ending May 21, 2022.

The Committee for Medicinal Products for Human Use (CHMP) issues a positive opinion to expand Novartis secukinumab indication to enthesitis-related arthritis (ERA) and juvenile psoriatic arthritis (JPsA).

Zachary S Wallace, MD, explains his approach to diagnosing and managing IgG4-related disease and some of the clinical trials that are on the horizon.

Janet Pope, MD, MPH, explains her treatment strategies for unresponsive patients with rheumatoid arthritis as well as clinical pearls of 2021.

Julie J Paik, MD, MHS, discusses the clinicoserological spectrum of inflammatory myopathy in the context of rheumatic diseases and how autoantibody profiles can help predict myositis phenotype and disease course.

Developing research into the specific alterations of dysbiosis and diseases like arthritis suggest possibly novel pathways to therapy development.

Leonard Calabrese, DO, explains the history of interferon history in rheumatology, immunology for the rheumatologist, and COVID-19 immunology regarding autoimmune and inflammatory manifestations.

Arthur Kavanaugh, MD, discusses his recent CCR East presentations “The Immunopathogenesis of Psoriatic Arthritis and Immunologically Targeted Therapy” and “Hot Topics in Rheumatoid Arthritis.”

Take 5 minutes to catch up on Rheumatology Network's highlights from the week ending May 14, 2022.

Anne Winkler, MD, discusses her upcoming CCR East presentation, “Targeting Lupus Nephritis.”

Of 185 outpatients that completed the questionnaire, 146 patients (78.9%) were considered to have poor adherence to exercise therapy.

While genetics are linked to gout diagnosis and lifestyle factors are related to risk, the association between healthy choices and risk mitigation remained unclear.

Rheumatoid arthritis is known risk factor for cardiovascular disease, but how much do you know about the association? Test your knowledge with this quiz.

In the double blinded study, patients were randomized to receive anifrolumab (300mg monthly), an intensified regimen of 3 x 900mg doses followed by 300mg monthly, or standard of care therapy with mycophenolate mofetil and oral glucocorticoids.

After years of frustration and failure, trials of targeted biologic therapy in systemic lupus erythematosus are beginning to show success. New drugs, including anifrolumab (Saphnelo) and belimumab (Benlysta), are paving the way for an exciting new era. However, this raises new questions as to how these novel therapeutics will be incorporated into future clinical practice.

One-year results from the PsABio study provide evidence on factors that may impact treatment selection and decisions in clinical practice.

Take 5 minutes to catch up on Rheumatology Network's highlights from the week ending May 7, 2022.

Pri-Med West presenter, Dr. Peng Thim Fan asks the questions that many rheumatologists have likely been contemplating now that disease treatment is so successful.

While some physicians might initially assume that oral medications like upadacitinib aren't as effective as an injection, but Dr. Fan explains that's not the case.

Janet E McDonagh, MD, FRCP, discusses the study “The Role of Age in Delays to Rheumatological Care in Juvenile Idiopathic Arthritis.”

Expert rheumatologist Dr. Peng Thim Fan explains that the effects of COVID-19 are still being examined.

According to investigators, pulmonary hypertension indicates an increased risk of mortality in patients with systemic sclerosis.

The cross-sectional analysis determined cognitive performance of patients with systemic lupus erythematosus was significantly lower when compared with controls in both motor speed and psychomotor speed domains.

The European Alliance of Associations for Rheumatology (EULAR) recommends screening and early management of cardiovascular disease in patients with radiographic axial spondyloarthritis.

“Biomarkers can be used to elucidate normal and pathological processes and to measure biological response to a therapeutic intervention,” investigators stated.

The American College of Rheumatology recommends that a treat-to-target strategy is followed for rheumatoid arthritis. Test your knowledge of how to maximize the potential benefits of this approach with this quiz.

In this Q&A, Gerd R. Burmester, MD, discussed the findings of his study that evaluated the exposure to ixekizumab, outcomes and medical history of patients with active psoriatic arthritis (PsA) who experienced adverse events.